株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

BCGワクチン市場:人口統計別(0〜18歳、19〜35歳) - 世界の機会分析および業界予測

BCG Vaccine Market by Demographics [Pediatrics (0-18 Years) and Adults (19-35 Years)] - Global Opportunity Analysis and Industry Forecast, 2017-2023

発行 Allied Market Research 商品コード 563324
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
BCGワクチン市場:人口統計別(0〜18歳、19〜35歳) - 世界の機会分析および業界予測 BCG Vaccine Market by Demographics [Pediatrics (0-18 Years) and Adults (19-35 Years)] - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日: 2017年09月01日 ページ情報: 英文 150 Pages
概要

当レポートでは、世界のBCGワクチン市場について調査し、市場の人口統計別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • 市場シェア分析
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
    • 影響分析
  • 治験

第4章 人口統計別市場

  • 概要
  • 小児(0〜18歳)
  • 成人(19〜35歳)

第5章 国別市場

  • 概要
  • インド
  • 中国
  • バングラデシュ
  • パキスタン
  • インドネシア
  • 日本
  • ブラジル
  • メキシコ
  • 南アフリカ
  • ケニア
  • タイ
  • アルゼンチン
  • コロンビア
  • チリ
  • シンガポール
  • その他

第6章 企業プロファイル

目次
Product Code: LI 04419

The global BCG vaccine market is estimated to reach $28,051 thousand by 2023, growing at a CAGR of 4.6% from 2017 to 2023, from $20,366 thousand in 2016. Bacillus Calmette-Guerin (BCG) vaccine is the only vaccine available for prevention of human forms of tuberculosis (TB). This vaccine is generally administered to children at birth in countries with high incidence of TB. In regions with low level of TB, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.

The global BCG vaccine market is driven by increase in prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, the increase in government initiatives and focus on immunization programs globally boost the market growth. However, side effects of BCG vaccine and a global shortage of BCG vaccine restrain this growth. Untapped market potential in developing regions is expected to present numerous opportunities for market development.

The global BCG vaccine market is segmented on the basis of demographics and country. Based on demographics, it is bifurcated into pediatrics (0-18 years), and adults (19-35 years. Based on country, it is analyzed across India, China, Bangladesh, Pakistan, Indonesia, Japan, Brazil, Mexico, South Africa, Kenya, Thailand, Argentina, Colombia, Chile, Singapore, and rest of the world.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global BCG vaccine market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

BY DEMOGRAPHICS

  • Pediatrics (0-18 Years)
  • Adults (19-35 Years)

BY COUNTRY

  • India
  • China
  • Bangladesh
  • Pakistan
  • Indonesia
  • Japan
  • Brazil
  • Mexico
  • South Africa
  • Kenya
  • Thailand
  • Argentina
  • Colombia
  • Chile
  • Singapore
  • Rest of the world
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Merck & Co., Inc.
  • Sanofi Pasteur
  • Japan BCG Laboratory
  • China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation)
  • Serum Institute of India Pvt. Ltd.
  • InterVax Ltd.
  • GreenSignal Bio Pharma Limited (GSBPL)
  • Statens Serum Institut

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS FOR STAKEHOLDERS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.1.1. Secondary research
    • 1.1.2. Primary research
    • 1.1.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. KEY FINDINGS OF THE STUDY
  • 2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
      • 3.2.2.1. Competitive intelligence of companies and their strategies
  • 3.3. MARKET SHARE ANALYSIS, 2016
  • 3.4. MARKET DYNAMICS
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
    • 3.4.4. Impact analysis
  • 3.5. CLINICAL TRIALS

CHAPTER 4 GLOBAL BCG VACCINE MARKET, BY DEMOGRAPHICS

  • 4.1. OVERVIEW
    • 4.1.1. Key market trends
    • 4.1.2. Growth factors and opportunities
    • 4.1.3. Market size and forecast
  • 4.2. PEDIATRICS (AGE 0-18 YEARS)
    • 4.2.1. Market size and forecast
  • 4.3. ADULTS (AGE 19-35 YEARS)
    • 4.3.1. Market size and forecast

CHAPTER 5 BCG VACCINE MARKET, BY COUNTRY

  • 5.1. OVERVIEW
    • 5.1.1. Key market trends
    • 5.1.2. Growth factors and opportunities
    • 5.1.3. Market size and forecast
  • 5.2. INDIA
    • 5.2.1. Market size and forecast
  • 5.3. CHINA
    • 5.3.1. Market size and forecast
  • 5.4. BANGLADESH
    • 5.4.1. Market size and forecast
  • 5.5. PAKISTAN
    • 5.5.1. Market size and forecast
  • 5.6. INDONESIA
    • 5.6.1. Market size and forecast
  • 5.7. JAPAN
    • 5.7.1. Market size and forecast
  • 5.8. BRAZIL
    • 5.8.1. Market size and forecast
  • 5.9. MEXICO
    • 5.9.1. Market size and forecast
  • 5.10. SOUTH AFRICA
    • 5.10.1. Market size and forecast
  • 5.11. KENYA
    • 5.11.1. Market size and forecast
  • 5.12. THAILAND
    • 5.12.1. Market size and forecast
  • 5.13. ARGENTINA
    • 5.13.1. Market size and forecast
  • 5.14. COLOMBIA
    • 5.14.1. Market size and forecast
  • 5.15. CHILE
    • 5.15.1. Market size and forecast
  • 5.16. SINGAPORE
    • 5.16.1. Market size and forecast
  • 5.17. REST OF THE WORLD
    • 5.17.1. Market size and forecast

CHAPTER 6 COMPANY PROFILES

  • 6.1. CHINA NATIONAL BIOTEC GROUP (A SUBSIDIARY OF CHINA NATIONAL PHARMACEUTICAL GROUP CORPORATION)
    • 6.1.1. Company overview
    • 6.1.2. Operating business segments
    • 6.1.3. Business performance
    • 6.1.4. Key strategic moves and developments
  • 6.2. GREENSIGNAL BIO PHARMA LIMITED
    • 6.2.1. Company overview
    • 6.2.2. Operating business segments
    • 6.2.3. Business performance
    • 6.2.4. Key strategic moves and developments
  • 6.3. INTERVAX LTD.
    • 6.3.1. Company overview
    • 6.3.2. Operating business segments
    • 6.3.3. Business performance
    • 6.3.4. Key strategic moves and developments
  • 6.4. JAPAN BCG LABORATORY
    • 6.4.1. Company overview
    • 6.4.2. Operating business segments
    • 6.4.3. Business performance
    • 6.4.4. Key strategic moves and developments
  • 6.5. MERCK & CO., INC.
    • 6.5.1. Company overview
    • 6.5.2. Operating business segments
    • 6.5.3. Business performance
    • 6.5.4. Key strategic moves and developments
  • 6.6. SANOFI PASTEUR
    • 6.6.1. Company overview
    • 6.6.2. Operating business segments
    • 6.6.3. Business performance
    • 6.6.4. Key strategic moves and developments
  • 6.7. SERUM INSTITUTE OF INDIA PVT. LTD.
    • 6.7.1. Company overview
    • 6.7.2. Operating business segments
    • 6.7.3. Business performance
    • 6.7.4. Key strategic moves and developments
  • 6.8. STATENS SERUM INSTITUT
    • 6.8.1. Company overview
    • 6.8.2. Operating business segments
    • 6.8.3. Business performance
    • 6.8.4. Key strategic moves and developments
Back to Top